F-gel (ketoprofen) 2.5% 30 g.


Manufacturer: Ukraine

Pain in muscles and joints caused by injuries or injuries. Tendovaginitises.



F-gel Composition
active substance: ketoprofen;

1 g of gel contains ketoprofen 25 mg;

Excipients: ethanol (96%), methylparaben (E 218), carbomer 980, tromethamine, lavender oil, neroli oil, purified water.

F-gel Dosage form


F-gel Pharmacotherapeutic group

Non-steroidal anti-inflammatory drugs for topical use. Ketoprofen.

ATC code M02A A10.

Pharmacological properties


The active substance of the drug F-gel® – ketoprofen – belongs to the group of nonsteroidal anti-inflammatory drugs derived from arylpropionic acid. Ketoprofen has analgesic and anti-inflammatory effects due to inhibition of cyclooxygenase 1 (COX-1), cyclooxygenase 2 (COX-2) and bradykinin, stabilization of lysosomal membranes and inhibition of macrophage migration. It has analgesic and anti-inflammatory activity both in the early stage (vascular phase) and in the late stage (cellular phase) of the inflammatory reaction. The drug also inhibits platelet aggregation.


When applied topically, ketoprofen is absorbed from the skin, penetrates locally into inflamed tissues and maintains a therapeutic concentration in them for a long time. Absorption to the systemic circulation is very low (only 5% of the administered dose) and is slow. When applying to the skin a gel containing from 50 to 150 mg of ketoprofen, the concentration of the active substance in the blood plasma after 5-8 hours is not more than 0.08-0.15 μg / ml, which has virtually no clinically significant effect on the body.

Basic physical and chemical properties

homogeneous, colorless, almost transparent gel with a specific odor.


Muscle and joint pain caused by injury or damage;


Hypersensitivity reactions, such as symptoms of bronchial asthma, allergic rhinitis or urticaria, have been reported with ketoprofen, fenofibrate, thiaprofenic acid, acetylsalicylic acid or other non-steroidal anti-inflammatory drugs;
hypersensitivity to any of the excipients;
presence in the anamnesis of skin manifestations of allergy with the use of ketoprofen, fenofibrate, tiaprofenic acid, blockers of ultraviolet (UV) rays or perfumes;
history of photosensitization reactions;
exposure to sunlight, including indirect sunlight and ultraviolet radiation in the solarium throughout the treatment period and for another 2 weeks after stopping treatment with the drug
damage to the integrity of the skin (damage, rash, eczema, injuries, skin infections).

The drug should not be used in children under 15 years of age.